[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes-t2dm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes-t2dm":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,40,69,105,129,157,200,227,254,283,303,335,357,379,408,429,454,481,501,523,543,569,593,616],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100633468","phase-3-evaluate-the-efficacy-and-safety-of-gzr33-injection-in-patients-with-type-2-diabetes-100633468",false,"NCT07527078","Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes","A Randomized, Open-label, Parallel-controlled, Multicenter Phase III Clinical Study Comparing the Efficacy and Safety of GZR33 Injection and Insulin Degludec Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antidiabetic Drugs","Inclusion Criteria:\n\n1. Subjects sign the Informed Consent Form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and are able to follow the contraindications and restrictions specified in this protocol.\n2. Male or female, aged ≥18 years at the time of informed consent..\n3. Body mass index (BMI) ≥18.5 and ≤35.0 kg\u002Fm2 at screening.\n4. According to the diagnostic criteria and classification of diabetes mellitus issued by the World Health Organization (WHO) in 1999, and the supplementary diagnostic criteria recommended by WHO for diagnosis with Hemoglobin A1c (HbA1c) (2011), the time to diagnose T2DM is ≥ 180 days at screening.\n5. Stable treatment with oral antidiabetic drugs for ≥ 90 days prior to screening.\n\nExclusion Criteria:\n\n1. History of hypersensitivity to ≥ 2 drugs with distinct mechanisms of action, or known hypersensitivity, allergic reactions, or intolerance to the investigational medicinal products or their excipients (glycerol, phenol, metacresol, zinc acetate dihydrate, sodium chloride, hydrochloric acid, sodium hydroxide).\n2. Female subjects who are pregnant, lactating at screening, or planning a pregnancy during the trial period.\n3. Confirmed or suspected type 1 diabetes mellitus or specific types of diabetes due to other causes (monogenic diabetes syndrome, cystic fibrosis-related diabetes, pancreatitis-induced diabetes, drug- or chemical-induced diabetes, etc.) prior to screening.\n4. Presence of any diseases that may affect HbA1c testing at screening, such as hemolytic anemia, aplastic anemia, hemoglobinopathy, etc., and in the investigator's judgment unsuitable for participation; or blood donation, blood loss \\> 400 mL, or blood transfusion within 90 days prior to screening.\n5. History of severe cardiovascular and cerebrovascular diseases within 180 days prior to screening.\n6. Significant hepatic or renal dysfunction or active infectious diseases at screening.\n7. Lifestyle (diet, exercise, work circadian rhythm, etc.) expected to change significantly during the trial and affect glycemic control; irregular three-meal intake (e.g., habitual skipping of breakfast); or unwillingness to comply with relevant lifestyle restrictions during the trial.\n8. Any other conditions that, in the investigator's judgment, may compromise subject safety or interfere with trial conduct, progress, or outcome.","ALL","18 Years",{"count":19,"type":20},350,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Evaluate the efficacy of GZR33 Injection and Insulin Degludec Injection (Tresiba®) in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs.",[26],"Type 2 Diabetes (T2DM)","RECRUITING","2026-06-29",{"date":30,"type":31},"2026-07-01","ACTUAL",{"date":33,"type":31},"2026-04-07",{"date":35,"type":20},"2027-04-17",{"name":37,"class":38},"Gan & Lee Pharmaceuticals.","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100645029","hcc-risk-and-monitoring-in-patients-with-type-2-diabetes-100645029","NCT07675187","HCC Risk and Monitoring in Patients With Type 2 Diabetes","Hepatocellular Carcinoma Risk Assessment and Surveillance in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosed with type 2 diabetes mellitus and clinically followed with regular outpatient visits.\n* FIB-4 index greater than 2.67 (calculated based on AST, ALT, and platelet count within the past 6 months).\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* HBsAg positive.\n* Anti-HCV positive and HCV RNA positive (patients with anti-HCV positive but negative HCV RNA are still eligible).\n* Prior history of hepatobiliary malignancies.\n* Undergoing regular abdominal ultrasound screening more than once per year.\n* Established diagnosis of liver cirrhosis via abdominal ultrasound or clinical evaluation.\n* Diagnosed with or treated for any malignancy within the past 2 years.\n* Women of childbearing potential or pregnant women.\n* Thrombocytopenia secondary to hematologic disorders.\n* Known history of human immunodeficiency virus (HIV) infection.\n* Concomitant use of medications that may interfere with PIVKA-II assay results (e.g., warfarin, vitamin K).",{"count":48,"type":20},2400,"3 Years","OBSERVATIONAL","Liver cancer is a significant malignancy in Taiwan. With the widespread implementation of antiviral therapies, hepatitis B and C-related liver cancer has gradually declined; however, metabolic dysfunction-associated liver cancer continues to increase, particularly among patients with type 2 diabetes mellitus (T2DM) who also present with significant liver fibrosis. Current clinical guidelines lack standardized recommendations for liver cancer screening in this specific population, and data from prospective randomized controlled trials remain scarce.This study is a prospective randomized controlled trial enrolling patients aged 18 years, diagnosed with T2DM, and with a FIB-4 \\> 2.67. Participants will be randomly assigned to either the surveillance group or the standard-care group. The surveillance group will undergo blood tests every 6 months to monitor liver function, AFP, and PIVKA-II, alongside the calculation of the GAAD score. The standard-care group will receive liver function tests every 6 months according to routine clinical practice. Abdominal ultrasound or computed tomography (CT) scans will be arranged by clinicians when clinically indicated. All participants will undergo abdominal ultrasound at baseline and at the end of the third year, with blood samples and clinical data collected periodically. The primary endpoint of this study is the tumor size at the time of liver cancer diagnosis. Secondary endpoints include liver cancer staging, number of liver cancer tumors, liver cancer incidence, the proportion of patients receiving curative treatment, and the degree of liver fibrosis as reflected by changes in FIB-4. This study expects to clarify the clinical benefits of a GAAD score-based surveillance strategy compared to standard care in T2DM patients with high FIB-4 scores, thereby providing evidence-based support for future liver cancer screening strategies and clinical guidelines.",[26,53],"Hepatocellular Carcinoma (HCC)",[55,56,57,58],"Type 2 Diabetes","Liver Cancer","Surveillance","Prospective Randomized Study","NOT_YET_RECRUITING","2026-06-23",{"date":62,"type":31},"2026-06-30",{"date":30,"type":20},{"date":65,"type":20},"2030-12-31",{"name":67,"class":68},"National Taiwan University Hospital","OTHER",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":39},"100624978","validation-of-hemoglobin-a1c-in-patients-with-inflammatory-arthritis-treated-with-sulfasalazine-100624978","NCT07416656","Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With Sulfasalazine","How Can We Prevent the Underdiagnosis of Diabetes and the Undertreatment of Known Diabetes in Patients With Inflammatory Arthritis Treated With Sulfasalazine?","DIA2SULFA","Inclusion Criteria:\n\n* Age ≥18 years\n* Treatment with sulfasalazine for at least 2 months prior to inclusion\n* Inflammatory arthritis diagnosis (Reumatoid Arthritis, Reaktive Arthritis, Axial spa, Psoriatic spondylitis, and Juvenil artrit)\n* HbA1c ≥38 mmol\u002Fmol obtained at least 2 months after sulfasalazine initiation OR a diabetes mellitus diagnosis (Type 1 diabetes mellitus, Type 2 diabetes mellitus, Malnutrition-related diabetes mellitus, Other specified diabetes mellitus (andre specificerede former for diabetes), and Unspecified diabetes mellitus (uspecificeret diabetes))\n* Can communicate in Danish\n* Informed consent including permission to upload glucose data and study ID to the Libreview Platform.\n\nExclusion Criteria:\n\n* Systemic treatment or local injections with glucocorticoids within the previous 2 months or planned within the following 4 weeks\n* Clinical conditions interfering with the interpretation of HbA1c expect for sulfasalazine alterations in red cell lifespan (etc. Dapson treatment)\n* Allergy towards the adhesive used in the CGM\n* Considered ineligible for participating (e.g. patients without decision-making capacity, , malignancy, terminal illness, ect.)",{"count":78,"type":20},75,"The purpose of this study is to examine whether the blood test Hemoglobin A1c (HbA1c) gives an accurate picture of blood glucose levels in patients with inflammatory arthritis who are treated with sulfasalazine. HbA1c is widely used to diagnose and monitor diabetes, but sulfasalazine can shorten red blood cell lifespan and thereby lower HbA1c values independently of actual glucose levels.\n\nThis may lead to underdiagnosis of diabetes in patients who develop diabetes during sulfasalazine treatment, and to undertreatment in patients with known diabetes due to falsely reassuring HbA1c values.\n\nThe study aims to answer two main questions:\n\n1. How many patients treated with sulfasalazine have undiagnosed diabetes despite having HbA1c values below the diagnostic threshold?\n2. Does HbA1c underestimate actual glucose levels when compared with continuous glucose monitoring (CGM) in patients with sulfasalazine-treated inflammatory arthritis, both in those with known diabetes and those that are not diagnosed with diabetes but have borderline HbA1c values (≥ 38 mmol\u002Fmol)?",[81,82,83,84,26],"Inflammatory Arthritis","Diabetes (DM)","Rheumatoid Arthritis (RA)","Type 1 Diabetes Mellitus",[86,87,88,89,90,55,91,92,93,94,95],"Validation of HbA1c","Sulfasalazine","Salazopyrin","Continuous glucose monitoring","CGM","Diabetes","Hemoglobin A1c","HbA1c","Type 1 Diabetes","Fasting blood glucose","2026-06-22",{"date":98,"type":31},"2026-06-25",{"date":100,"type":31},"2026-03-10",{"date":102,"type":20},"2026-10",{"name":104,"class":68},"Klavs Würgler Hansen",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":112,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":39},"100643809","phase-4-pleasure-pleasing-lovers-efficacy-arousal-satisfaction-and-uptake-research-on-eroxon-100643809","NCT07636161","PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)","PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon): A Pilot Randomized Trial of Eroxon® Gel as an Adjunct to Tadalafil in Young Men With Diabetes-Associated Erectile Dysfunction","Inclusion Criteria:\n\n* Male sex at birth\n* Age 18-40 years\n* Diagnosis of type 2 diabetes mellitus\n* Diagnosis of erectile dysfunction\n* Currently prescribed tadalafil\n* Have a sexual partner willing to complete a survey\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Severe psychiatric illness that would impair participation\n* Use of nitrates or contraindications to sexual activity\n* Known allergy to Eroxon® gel components\n* Participation in another interventional sexual health study","MALE","40 Years",{"count":115,"type":20},30,[117],"PHASE4","The purpose of this research study is to look at whether Eroxon® gel when used together with tadalafil, may help improve erectile function in men ages 18 to 40 who have type 2 diabetes.",[55,26],"2026-06-03",{"date":122,"type":31},"2026-06-09",{"date":124,"type":20},"2026-09",{"date":126,"type":20},"2027-09",{"name":128,"class":68},"University of Miami",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":39},"100617322","side-to-side-duodeno-ileostomy-versus-semaglutide-in-adults-with-obesity-and-type-2-diabetes-100617322","NCT07317115","Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes","Magnetic Compression Anastomosis in Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes (MAGvMED Study)","MAGvMED","Inclusion Criteria:\n\n* Body Mass Index (BMI) between 30 - 40 kg\u002Fm2 and qualifies for obesity treatment at the discretion of the treating investigator (i.e., must be assessed to qualify for both surgery and medication treatment to justify randomization).\n* Type 2 diabetes (T2D defined as HbA1c ≥ 6.5%).\n* Participant agrees to refrain from additional metabolic and bariatric (MBS) or reconstructive surgery that would affect body weight for the duration of the study.\n* Participant agrees to refrain from taking any additional semaglutide-containing or other GLP-1RA medication for the duration of the study, regardless of randomization assignment (i.e., Surgery or Medication).\n\nParticipant has been informed of the nature of the study and is willing and able to comply with requirements, including randomization, and provides written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Meets any of the contraindications for either treatment arm (Surgery: Magnet System; or Medication: semaglutide), thereby prohibiting randomization\n* Current or previous metabolic and bariatric surgery (MBS) treatment in the previous 12 months (e.g., sleeve gastrectomy, intragastric balloons, adjustable gastric banding).\n* Taking or treated with semaglutide, semaglutide-containing medications, or any other GLP-1RA medication in the previous 12 months.\n* Pregnant, lactating or planning pregnancy during the clinical study and follow-up period.\n* Currently participating in an investigational drug, biologic, or medical device or other interventional clinical study.\n* Presence of other anatomic or comorbid conditions, or medical, social or psychological conditions that, in the investigator's opinion, would contraindicate either treatment arm or could limit the participant's ability to participate in the clinical study or to comply with follow-up requirements.",{"count":138,"type":20},20,[140],"NA","Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).",[143,144,26],"Obesity (Disorder)","Obesity & Overweight",[146,147,148],"Magnet System","Semaglutide","GT Metabolic Solutions, Inc.","2026-05-18",{"date":151,"type":31},"2026-05-19",{"date":153,"type":31},"2026-03-18",{"date":155,"type":20},"2028-06",{"name":148,"class":38},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":179,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":39},"100605783","the-groceries-aimed-at-increasing-nutrition-study-100605783","NCT07167004","The GRoceries Aimed at Increasing Nutrition Study","Prompting a Switch From Refined Grains to Whole Grains in an Online Grocery Store Using Marketing Nudges and Financial Incentives","GRAINS","Inclusion Criteria:\n\n* Age 45 - 70 years.\n* Able to provide consent.\n* Resident of Philadelphia, Bucks, Delaware, Chester, or Montgomery Counties in Pennsylvania.\n* Consume \\\u003C5 servings of whole grains per week.\n* Use online grocery shopping at least once per month.\n* Have access to a credit or debit card to pay for groceries purchased.\n* Have reliable internet access.\n* Speak English.\n* Penn Medicine patient diagnosed with prediabetes or diabetes (identified using ICD-10 codes R73.03, E11).\n\nExclusion Criteria:\n\n* Does not meet all the inclusion criteria.\n* Not able to speak English.\n* Not able to provide consent.","45 Years","70 Years",{"count":168,"type":20},216,[140],"Only 2% of Americans meet the recommended levels of whole grain consumption, despite its association with reduced risk of type 2 diabetes. This study aims to assess if consumers with prediabetes or type 2 diabetes can be encouraged to switch from buying refined grain products to whole grain products when shopping for groceries online. The study will use personalized marketing strategies, with or without discounts which adjust based on purchasing behavior, to promote whole grain consumption.",[55,172,173,174,175,176,177,178,26],"Type II Diabetes Mellitus","Type II Diabetes","Pre-diabetes","Pre-diabetic","Pre-diabetic State","Type 2 Diabetes Mellitus (T2DM)","Type 2 Diabetes Mellitus",[180,181,182,183,184,185,186,187,188,189,190,191],"chronic disease","diabetes","diabetes mellitus","type II diabetes","type 2 diabetes","pre-diabetes","prediabetes","whole grains","behavioral economics","marketing nudges","financial incentives","food is medicine","2026-05-15",{"date":151,"type":31},{"date":195,"type":31},"2025-10-14",{"date":197,"type":20},"2027-02-16",{"name":199,"class":68},"University of Pennsylvania",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":208,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":211,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":4},"100604929","implementing-who-hearts-d-guidelines-in-bangladesh-for-diabetes-control-and-prevention-100604929","NCT07155902","Implementing WHO HEARTS-D Guidelines in Bangladesh for Diabetes Control and Prevention","Leveraging Community-to-facility Service Provision to Implement the World Health Organization HEARTS-D Guidelines in Bangladesh for Improving Diabetes Control and Prevention (HEARTS-D for Bangladesh)","T2D IR","Inclusion Criteria:\n\n1. Adult individuals, ≥35 years of age,\n2. Of either sex,\n3. Long-term residents in the study area (defined by being a homeowner or a resident for at least the past three years), and\n4. Willing to provide informed consent for study procedures and follow-up.\n\nExclusion Criteria:\n\n1. Individuals planning to migrate from the study area before completing the first 12-month follow-up period, and\n2. Individuals explicitly requesting exclusion from the study or unable to provide consent.","35 Years",{"count":210,"type":20},5000,[140],"Type-2 diabetes (T2D) is rising at an alarming rate in the low- and middle-income countries (LMIC). This rapid increase in the T2D burden has a particular impact on cities, where more than half the LMIC populations currently live and where 3 out of 4 people with T2D reside. In response to this growing global challenge, the World Health Organization (WHO) has emphasized (a) the need for an equitable and sustained improvement in the detection, treatment, and control of T2D, and (b) a rapid implementation of the WHO's evidence-based HEARTS-D module. However, currently, in most LMICs (such as Bangladesh), effective adoption of the WHO HEARTS-D module into routine urban primary care has been limited. These include suboptimal delivery mechanisms, poor uptake, weak monitoring system, and inadequate capacities. To address this, the investigators will evaluate a community-to-facility integrated strategy to implement WHO HEARTS-D module in the existing urban service delivery system in Bangladesh. First, the investigators will develop and optimize a community-to-facility integrated strategy for adopting the WHO HEARTS-D module using Implementation Mapping. Guided by this approach, the investigators will conduct mixed methods assessments to: (a) identify contextual factors, and (b) assess the implementation behavior of providers that may influence T2D care in cities. The investigators will then develop and optimize a suitable implementation strategy that can achieve high coverage, access and utilization of T2D care, specifically for urban poor populations, through iterative cycles of mixed methods qualitative assessments, implementation, and outcome measurements. For this aim, study staff will select the key stakeholders, primary care providers and CHWs as participants, based in 3 wards in Sylhet city of Bangladesh. Second, the investigators will evaluate the impacts of the optimized community-to-facility integrated strategy on implementation outcomes. The investigators will conduct a 2-arm, type 2, hybrid implementation-effectiveness randomized trial. The study will involve 20 municipal wards as clusters from Sylhet city (10 in each arm). This study compare the following strategies: (a) a community-to-facility integrated strategy for implementing the WHO HEARTS-D module and (b) a facility-only usual service delivery. The investigators will evaluate the implementation process by relevant outcomes based on the RE-AIM framework components: reach, effectiveness, implementation, and maintenance. Third, the investigators will compare the effectiveness of this strategy on T2D status. In a study sample of 10,000 randomly selected participants, the investigators will compare improvements in the prevalence of controlled T2D, treatment uptake and adherence to glucose-lowering therapy, T2D complications and awareness among participants in both study arms from baseline to end-line. Our study should guide the policymakers into effective implementation and sustainment of WHO HEARTS-D module that can be: (a) embedded within local organizational structures, and (b) adapted to similar contexts globally.",[26],[206,215,55,216,217],"HEARTS-D","Implementation Research","Non-communicable disease (NCD)","2026-05-07",{"date":220,"type":31},"2026-05-08",{"date":222,"type":20},"2026-07",{"date":224,"type":20},"2029-09",{"name":226,"class":68},"Florida International University",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":21,"phases":237,"briefSummary":238,"conditions":239,"keywords":244,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":4},"100596312","impact-of-pharmate-trial-on-glycemic-control-diabetes-knowledge-medication-adherence-and-quality-of-life-in-type-2-diabetes-patients-a-mixed-method-study-protocol-100596312","NCT07043816","Impact of PharmaTE Trial on Glycemic Control, Diabetes Knowledge, Medication Adherence and Quality of Life in Type 2 Diabetes Patients: A Mixed-Method Study Protocol","PharmaTE","Inclusion Criteria\n\n* Patients diagnosed with uncontrolled type 2 diabetes (defined as glycated haemoglobin \\[HbA1c\\] \\>7%) within the previous 12 months\n* Adults (18 to 65 years) of either gender\n* Prescribed at least one antidiabetic medication\n* Have access to either a telephone or a mobile phone\n* Treated in an outpatient facility in IBOH, RAK\n* Arabic-speaking patients\n* Patients who understand study information and are given written informed consent.\n\nExclusion Criteria:\n\n* Under 18 years old\n* Pregnant ladies\n* Patients admitted to the emergency department\n* Patients with severe hepatic or renal dysfunction\n* Diagnosed with type 1 DM or diagnosed with gestational diabetes\n* Having vision or hearing impairments and psychological problems\n* Immunocompromised patients, e.g., organ transplants, AIDS, cancer patients, and patients on immunosuppressant therapy\n* Patients with no or limited access to either a telephone or mobile phone, as well as those without reliable internet access","65 Years",{"count":236,"type":20},154,[140],"The goal of this clinical trial is to find out whether a pharmacist-led tele-educational program (PharmaTE trial) can help people with type 2 diabetes manage their condition better.\n\nThe main questions this study aims to answer are:\n\n1. Does the PharmaTE trial improve blood sugar control (HbA1c levels)?\n2. Does it help patients better understand their condition?\n3. Does it increase how well patients follow their medication schedule?\n4. Does it improve the quality of life for patients with type 2 diabetes?\n5. Is this type of tele-education program feasible and acceptable for patients?\n\nParticipants will:\n\nBe randomly placed into one of two groups:\n\nIntervention group: Receive five virtual education sessions with a clinical pharmacist over the phone or via Zoom (each lasting 20-30 minutes), in addition to their usual diabetes care.\n\nControl group: Continue receiving standard diabetes care from their healthcare team without the additional pharmacist-led sessions.\n\nComplete assessments at the beginning and end of the study. These include:\n\nA blood test for HbA1c\n\n, Questionnaires on diabetes knowledge, medication adherence, and quality of life\n\nSome participants in the intervention group will be invited for interviews after the sessions to share their experiences and opinions about the program.\n\nWho can join? Adults aged 18-65 with uncontrolled type 2 diabetes (HbA1c \\> 7%), receiving care at Ibrahim Bin Hamad Obaidullah Hospital in Ras Al-Khaimah, who speak Arabic and can provide consent.",[26,240,241,242,243],"Glycemic Control","Diabetes Knowledge","Medication Adherence","Quality of Life",[232],"2026-04-28",{"date":247,"type":31},"2026-04-29",{"date":249,"type":20},"2026-09-01",{"date":251,"type":20},"2027-12-31",{"name":253,"class":68},"Rabia Hussain",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":261,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":264,"briefSummary":265,"conditions":266,"keywords":272,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":39},"100634680","using-virtual-reality-to-improve-medical-training-100634680","NCT07542834","Using Virtual Reality to Improve Medical Training","Enhancing Osteopathic Medical Education Through Cinematic Virtual Reality","Inclusion Criteria: able to read and speak English, are age 18 years and older, and are a medical student enrolled at the Ohio University Heritage College of Osteopathic Medicine enrolled in the 2025-2026 academic year.\n\n\\-\n\nExclusion Criteria: unable to read and speak English, 17 years or younger, and are not a medical student enrolled at the Ohio University Heritage College of Osteopathic Medicine enrolled in the 2025-2026 academic year.\n\n\\-",true,{"count":263,"type":20},100,[140],"As the U.S. population ages, future physicians must be prepared to care for older adults with multiple health conditions and complex needs. This study will test whether cinematic virtual reality (VR)-an immersive, interactive learning tool-is more effective than traditional lectures in helping medical students learn about geriatric care. Students who complete the VR training will experience realistic patient scenarios that show what can go wrong in medical care and learn how to apply osteopathic principles to improve outcomes. Researchers will compare students' performance on a clinical skills assessment and explore their experiences with the VR training. The goal is to determine whether cinematic virtual reality can better prepare students for residency and improve their ability to provide compassionate, high-quality care for older adults.",[26,267,268,269,270,271],"Geriatric Syndromes","Disability Hearing","Disability Physical","Urinary Tract Infection(UTI)","Delirium Confusional State",[273],"virtual reality, type 2 diabetes, geriatric syndromes, disability, elder abuse and neglect","2026-04-14",{"date":276,"type":31},"2026-04-21",{"date":278,"type":20},"2026-04-15",{"date":280,"type":20},"2027-06-30",{"name":282,"class":68},"Ohio University",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":21,"phases":293,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":300,"leadSponsor":302,"locationsCount":39},"100622698","phase-2-evaluate-the-efficacy-and-safety-of-gzr101-80-injection-in-patients-with-type-2-diabetes-100622698","NCT07387003","Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes","A Multicenter Phase 2 Clinical Study to Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs or Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin","Inclusion Criteria:\n\n1. Subjects sign the Informed Consent Form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and are able to follow the contraindications and restrictions specified in this protocol.\n2. At the age of 18-75 (inclusive) at the time of informed consent, male or female.\n3. Body mass index (BMI) ≥18.5 and ≤35.0 kg\u002Fm2 at screening.\n4. According to the diagnostic criteria and classification of diabetes mellitus issued by the World Health Organization (WHO) in 1999, and the supplementary diagnostic criteria recommended by WHO for diagnosis with Hemoglobin A1c (HbA1c) (2011), the time to diagnose T2DM is ≥ 180 days at screening.\n\nExclusion Criteria:\n\n1. Confirmed or suspected type 1 diabetes mellitus or specific types of diabetes due to other causes (monogenic diabetes, cystic fibrosis, pancreatitis, drug- or chemical-induced diabetes, etc.) prior to screening.\n2. Grade 3 hypoglycemia within 3 months before screening.\n3. Subjects who have any diseases that may affect HbA1c testing at screening, or subjects who have donated blood, lost more than 400 mL of blood, or received blood transfusion within 3 months prior to screening.\n4. Diagnosis of active malignant tumor within 5 years prior to screening (excluding adequately treated or resected non-metastatic basal or squamous cell skin cancer, in situ cancer of cervix, or prostate cancer in situ), or with a high suspicion of potential malignant tumor at screening.","75 Years",{"count":292,"type":20},345,[294],"PHASE2","This study will be conducted to evaluate the efficacy and safety of GZR101-80 Injection in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs or Basal Insulin.",[26],"2026-04-10",{"date":278,"type":31},{"date":297,"type":20},{"date":301,"type":20},"2027-09-23",{"name":37,"class":38},{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":16,"minAge":311,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":315,"conditions":316,"keywords":321,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":39},"100614529","cgm-based-glycemic-analysis-after-esi-100614529","NCT07280780","CGM-Based Glycemic Analysis After ESI","Continuous Glucose Monitoring-Based Evaluation of Glycemic Fluctuations Following Epidural Steroid Injections: A Comparative Study by Diabetic Status","CGMSteroid","Inclusion Criteria:\n\n* Adults aged 20 to 60 years.\n* Patients scheduled for cervical or lumbar epidural steroid injection at the pain clinic.\n* Patients capable of understanding and using a Continuous Glucose Monitoring (CGM) device.\n\nExclusion Criteria:\n\n* Patients currently taking or administering steroid medications.\n* Patients with Type 1 Diabetes Mellitus.\n* Patients with Cushing's disease.\n* Patients who have received an epidural steroid injection within the last 3 months.\n* Patients with a known allergy to contrast media.\n* Patients taking anticoagulants or antiplatelet agents.\n* Patients unable to use a Continuous Glucose Monitoring (CGM) device.","20 Years","60 Years",{"count":314,"type":20},36,"The goal of this clinical study is to learn how blood glucose levels change after an epidural steroid injection (ESI) with dexamethasone in adults. It will specifically compare the glycemic response between patients with type 2 diabetes and those without diabetes.\n\nThe main questions it aims to answer are:\n\nDoes the injection cause higher or longer-lasting blood glucose elevation in diabetic patients compared to non-diabetic patients? How do the mean glucose level and Time in Range (TIR) change after the injection in both groups?\n\nResearchers will compare a Type 2 Diabetes group to a Non-Diabetes group to see the differences in glycemic fluctuations using a continuous glucose monitoring (CGM) device.\n\nParticipants will:\n\n* Wear a small CGM sensor on their arm for about 15 days to monitor blood glucose levels continuously\n* Receive an epidural steroid injection containing 5 mg of dexamethasone on Day 3\n* Visit the clinic 3 times (Day 1, Day 3, and Day 15) for sensor attachment, the injection procedure, and data collection",[26,317,318,319,320],"Hyperglycemia","Radicular Pain","Spinal Stenosis","Intervertebral Disc Herniation",[322,323,324,325,326],"epidural steroid injection","Continuous Glucose Monitoring","Dexamethasone","Glycemic Variability","Time in range",{"date":328,"type":31},"2026-04-09",{"date":330,"type":20},"2026-04-20",{"date":332,"type":20},"2026-12-31",{"name":334,"class":68},"Korea University Anam Hospital",{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":261,"sex":16,"minAge":17,"maxAge":234,"enrollmentInfo":343,"targetDuration":4,"studyType":21,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":4},"100632116","optimizing-lifestyles-through-increased-vegetable-rich-eating-pilot-study-100632116","NCT07509502","Optimizing Lifestyles Through Increased Vegetable-rich Eating Pilot Study","Building on the Dietary Guidelines: 3 Dietary Pattern (DG3D) Study - Testing a Teaching Kitchens and Food is Medicine Approach for Type 2 Diabetes Prevention","OLIVE Pilot","Inclusion Criteria:\n\n* 18-65 years of age\n* BMI between 25- 49.9 kg\u002Fm2\n* Live in a southern state (as classified by the US Census)\n* Be able to complete all survey assessments via computer or phone\n* Have a wi-fi connection at home or other site to access Zoom-delivered interventions\n* Have three or more type 2 diabetes risk factors (NIDDK Risk factors for T2DM)\n* Own a digital body weight scale, have regular access, or be willing to purchase one\n\nExclusion Criteria:\n\n* Currently participating in a weight loss program or taking weight loss medications\n* Has lost more than 10 pounds in the past 6 months\n* Diagnosed with major health or psychiatric diseases, drug or alcohol dependency, thyroid conditions, diabetes, or pregnancy\n* Pregnant (or have been pregnant in the last 6 months), anticipating on becoming pregnant in the next 3 months, or currently breastfeeding\n* Diagnosed with an eating disorder as screened by the Eating disorder Screen for Primary care \\[ESP\\].",{"count":344,"type":20},40,[140],"The goal of this pilot clinical trial is to examine how receipt of ingredients for a Mediterranean diet (with or without nutrition classes) impacts Type 2 Diabetes Mellitus risk factors among adults in the US South. The main question it aims to answer is:\n\n\\- Will greater improvements in diet quality (HEI Score) and body weight be seen in the group that receives grocery delivery and nutrition classes (TK+FiM) compared to the group receiving grocery delivery only (FiM only)?\n\nResearchers will evaluate the changes in diet quality and body weight among participants in each group to see which group experiences greater improvements.\n\nParticipants will:\n\n* be randomly assigned to either receive weekly grocery deliveries and attend weekly virtual nutrition classes for 4 weeks or receive weekly grocery deliveries only.\n* be asked to complete surveys\u002Fquestionnaires at the baseline and 4-week timepoints in the study.\n* be asked to participate in a post-study focus group to talk about their experiences during the intervention.",[26,144],"2026-04-06",{"date":350,"type":31},"2026-04-13",{"date":352,"type":20},"2026-06",{"date":354,"type":20},"2027-07",{"name":356,"class":68},"University of South Carolina",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":21,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":377,"locationsCount":138},"100609824","phase-3-a-study-to-evaluate-the-effect-of-obicetrapibezetimibe-10-mg-fixed-dose-combination-or-obicetrapib-10-mg-daily-on-top-of-guideline-recommended-lipid-lowering-therapy-in-participants-with-type-2-diabetes-andor-metabolic-syndrome-100609824","NCT07219602","A Study to Evaluate the Effect of Obicetrapib\u002FEzetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and\u002For Metabolic Syndrome","A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and\u002For Metabolic Syndrome (RUBENS Trial)","RUBENS","Inclusion Criteria:\n\n* fasting serum LDL-C ≥ 70 mg\u002FdL (≥1.81 mmol\u002FL)\n* Have fasting TG ≥150 mg\u002FdL (≥1.7 mmol\u002FL) and \\\u003C400 mg\u002FdL (\\\u003C4.5 mmol\u002FL)\n* Know diagnosis of T2DM OR have metabolic syndrome defined as fasting TG ≥150 mg\u002FdL (≥1.7mmol\u002FL) and \\\u003C400 mg\u002FdL (\\\u003C4.5 mmol\u002FL) and at least 2 risk factors\n* Are on stable guideline-recommended lipid-lowering therapy\n* Estimated glomerular filtration rate ≥15 mL\u002Fmin\u002F1.73 m2\n\nExclusion Criteria:\n\n* Have current or any previous history of New York Heart Association class III or IV heart failure or left ventricular ejection fraction \\\u003C30%\n* Have been hospitalized for heart failure within 5 years prior to Screening\n* Have uncontrolled severe hypertension\n* Have a formal diagnosis of homozygous familial hypercholesterolemia\n* HbA1c ≥10.0% (≥0.100 hemoglobin fraction) or a fasting glucose ≥270 mg\u002FdL (≥15.0 mmol\u002FL) at Screening\n* active liver disease",{"count":366,"type":20},300,[23],"This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and\u002For Type 2 Diabetes Mellitus.",[370,26,371],"Lipidemia","Metabolic Syndrome (MetS)","2026-03-06",{"date":100,"type":31},{"date":375,"type":31},"2025-12-11",{"date":155,"type":20},{"name":378,"class":38},"NewAmsterdam Pharma",{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":16,"minAge":387,"maxAge":388,"enrollmentInfo":389,"targetDuration":4,"studyType":21,"phases":390,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":39},"100627464","phase-3-vitamin-d-and-type-2-diabetes---treat-to-target-100627464","NCT07448974","Vitamin D and Type 2 Diabetes - Treat-To-Target","Vitamin D and Type 2 Diabetes, Treat-To-Target","D2d-TTT","Inclusion Criteria:\n\n1. High-risk prediabetes (\"at high risk for type 2 diabetes\") defined by meeting the following 2 prediabetes criteria established by the American Diabetes Association (ADA) in the 2010 clinical practice guidelines:\n\n   1. Fasting plasma glucose (FPG) 100-125 mg\u002FdL, inclusive\n   2. Hemoglobin A1c (HbA1c) 5.7-6.4%, inclusive\n2. Age 30-74 years, inclusive\n3. Body Mass Index ≥ 23.0 and ≤ 35.0 kg\u002Fm2\n4. Provision of signed and dated written informed consent prior to any study procedures.\n\n   Exclusion Criteria:\n5. History of diabetes (ICD10 diabetes code E08.X through E13.X) or meeting a diabetes glycemic criterion at screening, as defined by the ADA guidelines (FPG ≥ 126 mg\u002FdL or HbA1c ≥ 6.5%).\n6. History (past 2 years) of hyperparathyroidism, symptomatic or asymptomatic (i.e., radiographic) nephrolithiasis or hypercalcemia.\n7. Any medical condition (past 2 years) that in the opinion of the site investigator may increase risk for nephrolithiasis or hypercalcemia during the trial (e.g., sarcoidosis).\n8. If older than 70 years, history (past 1 year) of a fall.\n9. Use of tanning devices within 12 weeks of the baseline visit and unwilling to stop use of tanning devices for the duration of the study.\n\n   Medications and Supplements\n10. Use (past 6 months) of hypoglycemic pharmacotherapy (oral or injectable medication approved by the FDA for type 2 diabetes) for any condition (e.g., prediabetes, diabetes, polycystic ovarian syndrome, MASLD, sleep apnea) or any other medication that may affect glycemia (e.g., hydroxychloroquine)\n11. Current use of medications approved by the FDA for weight management (e.g., incretin receptor agonists) or planned use during the study.\n12. Use of supplements containing vitamin D at total doses higher than 1000 IU\u002Fday within 8 weeks of the baseline visit and unwillingness to limit vitamin D supplementation dosage to no higher than 1000 IU\u002Fday during the study. Because supplements vary widely in vitamin D content (e.g., may include cod liver or cod liver oi), participants will bring all supplements to the site for a review by the research team.\n13. Use of supplements containing calcium at total doses higher than 600 mg\u002Fday within 1 week of the baseline visit and unwillingness to limit calcium supplementation dosage to no higher than 600 mg\u002Fday during the study.\n14. Current use of medications or conditions (e.g., untreated celiac disease) that would interfere with the absorption or metabolism of vitamin D.\n15. Use of an anticonvulsant drug started within 6 months of screening. Stable regimen of anticonvulsants is allowed.\n16. History of intolerance to vitamin D supplements, allergic to any content of the study drug or unwilling to take vitamin D supplements (e.g., someone who eats a vegan diet and would object to the cholecalciferol ingredient which is produced from cholesterol extracted from sheep wool harvested from healthy living sheep).\n\n    Other Medical History\n17. Severe symptomatic cardiovascular disease based on history (unstable angina, dyspnea on exertion, paroxysmal nocturnal dyspnea, arrhythmia, congestive heart failure NYHA class II or higher, claudication)\n18. History (past 1 year) of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft.\n19. History (past 1 year) of cerebrovascular disease (stroke, transient ischemic attack).\n20. Any type of cancer (past 5 years) except for basal cell skin cancer. Prostate cancer (for men over age 55) or well-differentiated thyroid cancer not expected to require treatment (except for suppression with thyroid hormone) over the next 3 years, are not exclusions. People with history of squamous cell cancer of the skin, which was completely excised and with no evidence of metastases, are eligible.\n21. History (past 6 months) of treatment with oral (for \\> 7 days) or intravenous glucocorticoids or disease likely to require oral or intravenous glucocorticoid therapy during the study. Inhaled glucocorticoid use is not an exclusion. Epidural or intra-articular glucocorticoid injections are not exclusions, but study visits need to be conducted at least two weeks after the injection. Persons with adrenal insufficiency treated with physiologic doses of glucocorticoids who are otherwise stable are not excluded.\n22. History (past 1 year) of substance abuse or unstable psychiatric disorder that in the opinion of the site investigator would impede competence or adherence with study procedures or hinder completion of the study or increase risk.\n23. History of bariatric surgery (e.g., Roux-en-Y gastric bypass, gastric sleeve) or planned bariatric surgery in the next 2 years.\n24. Extreme (over 18 hours) intermittent fasting diets because prolonged fasting downregulates CYP2R1 activity.\n25. A life-threatening event within 30 days of screening or currently planned major surgery.\n26. Any other active medical condition (including but not limited to liver disease, wasting illness, HIV, tuberculosis, oxygen-dependent chronic obstructive pulmonary disease, organ transplant, Cushing's syndrome) that in the opinion of the site investigators would interfere with the study objectives, impede competence or adherence with study procedures or increase risk.\n27. Uncontrolled hypertension (systolic blood pressure \\> 160 mm Hg or diastolic blood pressure \\> 100 mm Hg).\n28. Poor venous access.\n\n    Laboratory Evaluation\n29. Serum liver transaminase higher than 3 times the normal range for the clinical site's laboratory, within 18 months of screening.\n30. Anemia (hematocrit \\\u003C 32 for women, \\\u003C 36 for men), whole blood transfusion (within 18 months of screening) or chronic requirement, whole blood donation (within 3 months of screening) or other condition (hemolysis, hemoglobinopathy) rendering HbA1c results unreliable as indicator of chronic glycemia. Participants who donate platelets are not excluded.\n31. Low platelet count (\\\u003C 100,000) within 18 months of screening.\n32. Chronic kidney disease, defined as estimated glomerular filtration rate \\[GFR\\] \\\u003C 50 mL\u002Fmin per 1.73 m2 from creatinine level and GFR calculated by the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations that omit race within 18 months of screening.\n33. Hypercalcemia, defined as serum calcium concentration ≥ upper limit of normal within 18 months of screening.\n34. Hypercalciuria, defined as spot urine (morning void) calcium-creatinine ratio \\> 0.275 within 18 months of screening.\n35. Baseline serum 25(OH)D level greater than 100 ng\u002FmL.\n\n    Other\n36. Participation (within 30 days of screening) in another interventional research study, and unwillingness to refrain from participating in another intervention study during the study.\n37. Previous randomization in the study. Participants who did not qualify after screening may be screened again if the prior reason for exclusion has been addressed (e.g., high blood pressure is treated).\n38. Any other reason that in the opinion of the site investigator would interfere with the study objectives, impede adherence with study procedures or hinder completion of the study or increase risk.\n\n    Women only\n39. Pregnancy (past 1 year by report or positive pregnancy test at screening), intent to become pregnant in the next 2 years. History of gestational diabetes is not an exclusion criterion.\n40. Currently breastfeeding.\n41. Use of oral contraceptives or menopausal hormone therapy started within 3 months of baseline. .\n\n    Continuous Glucose Monitoring specific\n42. Regular use of personal CGM and unwillingness to refrain from using personal CGM for the duration of the study.\n43. Use of hydroxyurea or regular use of high doses of acetaminophen (may impact CGM).\n44. Extensive skin changes (e.g., skin breakdown, rash) making CGM sensor use problematic.\n45. Significant skin sensitivity to adhesive (making CGM sensor unfeasible).","30 Years","74 Years",{"count":263,"type":20},[23],"This study tests whether taking a weekly dose of vitamin D, with the dose adjusted to reach a target blood vitamin D level, can help control blood sugar levels in adults at high risk of developing type 2 diabetes (prediabetes).\n\nResearch suggests that vitamin D may play a role in blood sugar control. The goal of this study is to see whether adjusting the dose of vitamin D to reach a specific blood vitamin D level improves blood sugar control compared with a placebo (a look-alike pill without vitamin D).\n\nOne hundred adults aged 30 to 74 with prediabetes will take part. Participants will be randomly assigned (by chance) to receive either weekly vitamin D supplements or a placebo. Neither the participants nor the research team will know which group a participant is in during the study.\n\nParticipants in the vitamin D group will start with one specific dose. After three months, a blood test will be used to decide whether the dose should stay the same or be increased to reach the target vitamin D level. Participants in the placebo group will continue taking the placebo each week.\n\nAll participants will be followed for about 18 months. During the study, they will attend scheduled study visits, have blood tests, and wear a continuous glucose monitor, a small device that measures blood sugar levels throughout the day and night. The research team will also make periodic phone calls to check on health changes, medication use, and study participation.\n\nThe main outcome of the study is the proportion of time that the participants' blood sugar levels remains in a healthy range.",[393,26],"Prediabetes",[395,396,397,398,186,184],"vitamin D","cholecalciferol","continuous glucose monitoring","diabetes prevention","2026-03-03",{"date":401,"type":31},"2026-03-05",{"date":403,"type":20},"2026-05",{"date":405,"type":20},"2031-03",{"name":407,"class":68},"Tufts Medical Center",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":261,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":414,"targetDuration":416,"studyType":50,"phases":4,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":39},"100626555","the-establishment-of-hong-kong-diabetes-steatotic-liver-disease-register-100626555","NCT07437157","The Establishment of Hong Kong Diabetes Steatotic Liver Disease Register","Inclusion Criteria:\n\n* T2DM.\n* Aged ≥ 18 years.\n* Able and willing to give Informed written consent.\n\nExclusion Criteria:\n\n* Type 1 diabetes.\n* Terminal illness such as malignancy with limited life expectancy.\n* Any condition, as judged by the investigators, as ineligible to participate in this study.",{"count":415,"type":20},1000,"15 Years","Liver is an important organ in maintaining energy homeostasis. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease locally and globally. MASLD and type 2 diabetes mellitus (T2DM) are closely related with alarmingly high prevalence of MASLD in people with T2DM, along with the escalated risk of adverse clinical outcomes. Our group has reported that around 70% of people with T2DM have increased controlled attenuation parameter (CAP) suggestive of hepatic steatosis and one out of six had advanced liver fibrosis as evidenced by increased liver stiffness measurements (LSM). Despite its prevalence, close relationships and potential consequences, the mechanisms underlying the complex interconnections between MASLD and T2DM are not fully understood. MASLD is associated with a twofold higher risk of developing T2DM, independent of obesity and other common metabolic risk factors. This risk increases with the severity of MASLD, such that patients with more advanced stages of liver fibrosis are at a higher risk of developing T2DM. Moreover, the progression from hepatic steatosis to fibrosis is an important, yet not fully understood, step towards cirrhosis and end-stage liver disease. Identification of clinical predictors and biomarkers to select individuals with MAFLD for close monitoring is pivotal to prevent the sinister outcomes. To date, longitudinal cohorts with paired biobank focused on people with diabetes and comorbid MASLD for investigating the clinical courses and biomarkers for prediction of outcomes are lacking. We hypothesized that Hong Kong Chinese T2DM with comorbid steatotic liver disease have unique clinical courses and special biomarkers for predicting the progression to advanced liver fibrosis. The aims of this study are: 1) establish a prospective cohort of people with T2DM and comorbid steatotic liver disease accompanied with the setting up of a biobank; 2) elucidate the clinical courses and outcomes of Hong Kong Chinese T2DM with comorbid steatotic liver disease; 3) identify potential diagnostic markers of advanced liver fibrosis in people with T2DM and comorbid steatotic liver disease in Hong Kong. The primary outcome measure will be all-cause mortality and secondary outcome measure will be fatal and non-fatal CVD, heart failure, hospitalizations, NT-proBNP levels, and novel diagnostic markers of MASH in people with T2DM comorbid with MASLD.",[419,26],"Metabolic Dysfunction-Associated Steatotic Liver Disease","2026-02-25",{"date":422,"type":31},"2026-02-27",{"date":424,"type":31},"2025-06-11",{"date":426,"type":20},"2027-02-28",{"name":428,"class":68},"Chinese University of Hong Kong",{"id":430,"slug":431,"hasResults":11,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":16,"minAge":387,"maxAge":166,"enrollmentInfo":436,"targetDuration":4,"studyType":21,"phases":437,"briefSummary":438,"conditions":439,"keywords":441,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":39},"100611887","glucagon-resistance-in-patients-with-masld-and-t2dm-100611887","NCT07246421","Glucagon Resistance in Patients With MASLD and T2DM","Mechanisms for Glucagon Resistance as Driver of Metabolic Associated Steatotic Liver Disease and Cardiovascular Disease in Humans With Type 2 Diabetes","Inclusion Criteria:\n\n* BMI \\> 26 kg\u002Fm²\n* confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) min. 6 months prior enrollment\n* steatosis FF% \\> 5,6% on MR spectroscopy for MAFLD group\n\nExclusion Criteria:\n\n* Alcohol abuse (\\>10 units per week for both sexes) or other substance abuse\n* Smoking\n* Current or previous malignant disease\n* Blood donation within the last 3 months prior to the study day\n* Participation in studies involving radioactive isotopes within the past 3 months\n* Pregnancy\n* Severely dysregulated type 2 diabetes mellitus (haemoglobin A1c ≥ 100 mmol\u002Fmol)\n* C-peptide \\\u003C 200 pmol\u002FL\n* Previous acute myocardial infarction (AMI)\n* Clinical symptoms of heart failure\n* Current or previous malignant disease\n* Known ongoing systemic disease, except for dyslipidaemia and hypertension\n* Regular use of medication that may affect lipid and glucose metabolism, including insulin treatment, regular use of over-the-counter medications, and hormonal contraception. Exceptions:\n\n  1. Participants treated with statins may be included following a 2-week washout period prior to the experimental study day.\n  2. Participants receiving oral glucose-lowering therapy for T2DM and antihypertensive medication may be included provided that medication is withheld on the study day only.\n  3. Participants receiving weekly injectable glucagon-like peptide-1 receptor agonists (GLP-1 analogues) may be included following a 1-week washout period prior to the study day.",{"count":5,"type":20},[140],"The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD).\n\nThe main questions it aims to answer are:\n\n1. Is the sensitivity to glucagon with respect to hepatic FA oxidation and suppression of VLDL-TG secretion impaired in humans with T2DM and MASLD?\n2. Is glucagon resistance and MASLD reflected in an aberrated lipidomic\u002Fmetabolomic profile in blood and adipose tissue?\n\nResearchers will compare patients with T2DM with and without MASLD to see if the response to basal and high levels of glucagon differs between the groups.\n\nParticipants will attend 2 short visits and 1 full-day visit, including:\n\n* Body scan (DXA) to check fat and bone composition\n* MRI to measure liver fat.\n* Blood tests.\n* Ultrasound to check liver stiffness and scarring.\n* Fat biopsies\n* 8-hour hormone (including glucagon) and tracer infusion\n* PET-CT scans",[440,26],"Metabolic Associated Fatty Liver Disease",[442,443,444],"MASLD","Glucagon","Glucagon Resistance","2026-02-03",{"date":447,"type":31},"2026-02-04",{"date":449,"type":31},"2026-01-29",{"date":451,"type":20},"2028-07-31",{"name":453,"class":68},"University of Aarhus",{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":463,"conditions":464,"keywords":467,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":39},"100614969","sexual-activity-and-hypoglycemia-risk-in-adults-with-type-1-or-type-2-diabetes-using-insulin-therapy-and-continuous-glucose-monitoring-100614969","NCT07286500","\"Sexual Activity and Hypoglycemia Risk in Adults With Type 1 or Type 2 Diabetes Using Insulin Therapy and Continuous Glucose Monitoring\"","\"Impact of Sexual Activity on Hypoglycemia Risk in Adults With Type 1 and Type 2 Diabetes Under Insulin Therapy and Continuous Glucose Monitoring (CGM)\"","SEX-HYPO-CGM","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Diagnosis of type 1 or type 2 diabetes.\n* Current use of a continuous glucose monitoring (CGM) system.\n* Treatment with insulin therapy in any regimen.\n* Ability to operate the CGM application and mark the start of sexual activity.\n* Willingness to participate for 3 months.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Inability to independently use the CGM application.\n* No sexual activity during the study period.\n* Withdrawal of consent at any time.\n* Any condition that, in the opinion of the investigator, prevents safe participation.",{"count":263,"type":20},"This observational study examines whether sexual activity influences the risk of hypoglycemia in adults with type 1 or type 2 diabetes treated with insulin therapy and using continuous glucose monitoring (CGM). Many patients report fear of hypoglycemia during or after sexual activity, which may affect their quality of life and willingness to engage in intimate relationships. However, no systematic research has been conducted on this topic, largely due to the sensitive nature of sexual health and the previous lack of tools to remotely monitor glucose profiles.\n\nThe study uses CGM systems (LibreView or Dexcom Clarity) to evaluate glucose changes during and up to 6 hours after sexual activity. Participants will mark the start of sexual activity in their CGM application using a neutral symbol (such as a heart icon). Data will be collected remotely through secure, certified platforms without the need for discussing details of intimate life. Glucose profiles from days with and without sexual activity will be compared. Each participant will be observed for 3 months.\n\nThe study will include 100 adults with type 1 or type 2 diabetes who use CGM and insulin therapy. By analyzing episodes of glucose levels below 70 mg\u002FdL during or after sexual activity, the study aims to determine whether sexual activity is associated with an increased risk of hypoglycemia. Findings may help to better understand patient concerns, reduce unnecessary fear, and develop future clinical recommendations for safe sexual activity in individuals treated with insulin.",[465,26,466],"Type 1 Diabetes (T1D)","Hypoglycemia",[468,466,469,323,90,470,94,55,471],"Sexual Activity","Glucose Variability","Insulin Therapy","Diabetes Complications","2025-12-02",{"date":474,"type":31},"2025-12-16",{"date":476,"type":31},"2025-07-30",{"date":478,"type":20},"2028-07-10",{"name":480,"class":68},"Medical University of Warsaw",{"id":482,"slug":483,"hasResults":11,"nctId":484,"briefTitle":485,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":261,"sex":16,"minAge":17,"maxAge":487,"enrollmentInfo":488,"targetDuration":4,"studyType":21,"phases":489,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":497,"leadSponsor":499,"locationsCount":39},"100610486","role-of-endothelial-dysfunction-on-exercise-pressor-reflex-in-type-2-diabetes-100610486","NCT07228208","Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes","Inclusion Criteria:\n\n* Type 2 Diabetes: 18 - 80 years old, able to give informed consent, \\> 6 months post-diagnosis, \\> 6 months stable medications for management\n* Healthy controls: 18 - 80 years old, able to give informed consent\n\nExclusion Criteria:\n\n* Type 2 Diabetes: Type 1 diabetes, symptomatic coronary artery disease, cardiovascular event in last year (MI, stroke), uncontrolled or unmanaged hypertension (\\>160\u002F90 mmHg), heart failure, renal impairments, current or recent (\\\u003C6 months) tobacco use, hormone replacement therapy, documented neuromuscular disorders, pregnancy\n* Healthy Controls: Same as listed in Type 2 Diabetes with Type 2 Diabetes as an exclusion factor","80 Years",{"count":344,"type":20},[140],"Exaggerated blood pressure responses to exercise in individuals with Type 2 Diabetes significantly increase the risk of heart attack, stroke, and cardiovascular death, while also limiting exercise capacity and therapeutic benefits of physical activity. This research will determine whether impaired blood vessel function and excessive cellular damage from oxygen-containing molecules cause these dangerous blood pressure responses during exercise. The findings will establish whether targeting cellular antioxidant systems represents a new therapeutic approach to improve exercise tolerance and reduce cardiovascular risk in t Americans living with diabetes.",[26,492],"Endothelial Dysfunction","2025-11-12",{"date":495,"type":31},"2025-11-14",{"date":249,"type":20},{"date":498,"type":20},"2031-12-31",{"name":500,"class":68},"Medical College of Wisconsin",{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":290,"enrollmentInfo":508,"targetDuration":4,"studyType":21,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":522},"100597899","phase-3-a-study-of-bgm0504-in-participants-with-type-2-diabetes-in-indonesia-100597899","NCT07064486","A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia","A Phase 3, Randomized, Open Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n* ○ Have been diagnosed with type 2 diabetes mellitus (T2DM);\n\n  * Be on stable treatment with unchanged dose of metformin ≥1500 mg\u002Fday or \\\u003C1500 mg\u002Fday but ≥1000 mg\u002Fday (the maximum tolerated dose) for at least 8 weeks prior to screening\n  * Have a BMI ≥23 kilograms per meter squared (kg\u002Fm²) at screening;\n  * Be of stable weight (± 5%) for at least 3 months before screening;\n  * Have HbA1c between ≥7.5% and ≤11.0% at screening\n\nExclusion Criteria:\n\n* ○ Previous diagnosis of type 1 diabetes, special type diabetes;\n\n  * Have suffered the malignancy within the past 5 years (except cured basal cell carcinoma of the skin, cervical carcinoma in situ), or being evaluated for an underlying malignancy;\n  * Have the acute or chronic pancreatitis;\n  * Known to be allergic to 3 or more kinds of foods or medications, or allergic to GLP-1 agonist or metformin, or have a severe allergic disease (asthma, urticaria, eczematous dermatitis, etc.) at screening;\n  * Have a serious mental illness or speech impediment and be unable to fully understand the study;\n  * Suspected or confirmed history of alcohol or drug abuse;\n  * Have had a history of ≥2 severe hypoglycemic episodes in the past 1 year;\n  * Other conditions that may impact the assessment of investigational products, as determined by the Investigator.",{"count":509,"type":20},477,[23],"This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes",[26],"2025-10-27",{"date":515,"type":31},"2025-10-28",{"date":517,"type":31},"2025-07-04",{"date":519,"type":20},"2026-07-31",{"name":521,"class":38},"BrightGene Bio-Medical Technology Co., Ltd.",4,{"id":524,"slug":525,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":487,"enrollmentInfo":530,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":541,"locationsCount":39},"100604965","salivary-cortisol-and-hypercortisolism-in-type-2-diabetes-100604965","NCT07156370","Salivary Cortisol and Hypercortisolism in Type 2 Diabetes","Study to Explore the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Assess the Correlation Between Salivary Cortisol and Glucose Levels","Inclusion Criteria:\n\n1. Aged between 18 and 80 years.\n2. Meets the definition of difficult to control type 2 diabetes:\n\nHbA1c level between 7.5% and 11.5%, AND Taking 3 or more anti-hyperglycemic drugs. OR Taking insulin and other anti-hyperglycemic drugs. OR Taking 2 or more anti-hyperglycemic drugs AND a.) the presence of 1 or more micro-vascular or macro-vascular complication (retinopathy, diabetic nephropathy and chronic kidney disease, diabetic neuropathy, atherosclerotic heart disease with diabetes); AND\u002FOR b.) concomitant hypertension requiring 2 or more anti-hypertension medications.\n\nExclusion Criteria:\n\n1. Patients with Type 1 diabetes, new-onset diabetes (\\\u003C1 year duration), or other specific types of diabetes.\n2. History of systemic glucocorticoid use within the last 3 months (inhaled or topical agents are not exclusionary).\n3. Pregnant or lactating.\n4. Presence of severe cardiac, hepatic, renal, or other major organ dysfunction.\n5. History of acute diabetic complications, such as diabetic ketoacidosis or hyperosmolar hyperglycemic state, within the last 3 months.\n6. Presence of diseases that significantly affect metabolism, such as malignancy or autoimmune disorders.\n7. Inability to tolerate adhesive tape, severe skin conditions at the sensor placement site, or presence of a psychiatric illness or cognitive impairment that would interfere with study compliance.\n8. A known diagnosis of Cushing's syndrome, or currently receiving treatment with any of the following: mifepristone, metyrapone, osilodrostat, ketoconazole, fluconazole, aminoglutethimide, etomidate, octreotide, larazotide, long-acting octreotide, or pasireotide.\n9. Excessive alcohol consumption (defined as \\>14 units per week for males or \\>7 units per week for females).\n10. Severe, untreated sleep apnea.\n11. Night shift workers (defined as being awake between 11:00 PM and 7:00 AM).\n12. Known allergy or severe reaction to dexamethasone.",{"count":531,"type":20},500,"The goal of this observational study is to explore the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes despite receiving standard-of-care therapies. Additionally, the study will evaluate the correlation between salivary cortisol levels and glycemic control.",[534,26],"Hypercortisolism","2025-09-04",{"date":537,"type":31},"2025-09-05",{"date":539,"type":20},"2025-09-01",{"date":251,"type":20},{"name":542,"class":68},"Shanghai 6th People's Hospital",{"id":544,"slug":545,"hasResults":11,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":166,"enrollmentInfo":551,"targetDuration":4,"studyType":21,"phases":553,"briefSummary":554,"conditions":555,"keywords":556,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":567,"locationsCount":4},"100603660","phase-2-triglytza-versus-metformin-in-obese-adult-type-2-diabetes-t2dm-patients-over-24-weeks-of-treatment-100603660","NCT07139405","TRIGLYTZA® VERSUS METFORMIN IN OBESE ADULT TYPE 2 DIABETES (T2DM) PATIENTS OVER 24 WEEKS OF TREATMENT","A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE II TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND SUPERIORITY OF TRIGLYTZA® OVER METFORMIN IN PATIENTS WITH INADEQUATE GLYCEMIC CONTROL OVER 24 WEEKS OF TREATMENT","RESILIENCE","Inclusion Criteria:\n\n1. Males and females, age 18 and ≤70 at time of screening visit\n2. WOCBP must have negative serum or urine pregnancy test (min sensitivity 25 IU\u002FL or equivalent HCG) within 24 hours prior to the start of the study\n3. Women must not be breastfeeding\n4. Inadequate BG control with Metformin defined as a screening HbA1c of ≥7.0 and ≤ 10.5 at the screening visit\n5. Subjects should have been taking the same daily dose of Metformin for at least 8 weeks prior to the enrolment visit and subjects must not receive other antihyperglycemic medications within the 12 weeks prior to screening\n6. FPG ≥140 mg\u002FdL\n7. BMI ≥28 and ≤40\n8. Grade 1 hypertension defined as 140-159 systolic and 90-99 diastolic mmHg if patients is not receiving anti-hypertensive medication at the time of screening \u002F or has never received anti-hypertensive medication.\n\n   If patient is receiving anti-hypertensive medication at the time of screening and their BP is controlled, BP should be within the normal range of \\\u003C120-139 systolic and \\\u003C80-89 diastolic.\n\n   Patients receiving anti-hypertensive medication at the time of screening and for which their hypertension is uncontrolled, will be excluded\n9. eGFR ≥ 60 ml\u002Fmin\n\nExclusion Criteria:\n\n1. Patients with Type 1 Diabetes\n2. Patients with history of ketoacidosis\n3. Subjects at serious risk of GI adverse events per the discretion of the study site investigator (e.g current or recent history of GI bleeding ulceration, or perforation)\n4. Subjects with a planned radiologic study with IV contrast, surgery, or other planned procedures that may predispose them to metformin-associated lactic acidosis\n5. Subjects with a history of uncontrolled hyperglycemia (\\>15.0 mmol\u002FL) after an overnight fast that required rescue therapy\n6. Impaired kidney function defined as eGFR ≤60 mL\u002Fmin\n7. Subjects taking any prohibited medications.\n8. Any of the following cardiovascular (CV)\u002Fvascular diseases within 3 months of the screening visit:\n\n   1. Myocardial infarction (MI)\n   2. Cardiac surgery or revascularization (coronary artery bypass surgery, Coronary Artery Bypass Graft \\[(CABG\\]\u002FPercutaneous transluminal coronary angioplasty (PTCA)\\]\n   3. Unstable angina\n   4. Unstable congestive heart failure (CHF)\n   5. Transient ischemic attack (TIA) or significant cerebrovascular disease\n   6. Unstable or previously diagnosed arrhythmia\n   7. Congestive heart failure, defined as New York Heart Association (NYHA) Class III and IV, unstable or acute heart failure and\u002For known left ventricular ejection fraction of ≤40%.\n   8. Acute coronary syndrome, stroke or transient ischemic attack within 3 months prior to the informed consent\n9. Previous bariatric surgery\n10. Previous bariatric surgery\n11. Treatment with anti-obesity drugs within 3 months prior to screening visit\n12. Subjects with COPD\n13. Subjects with active liver disease\n14. Subjects with active renal disease\n15. Subjects with autoimmune diseases e.g. Lupus, Psoriasis\n16. Subjects with HIV \u002F AIDS\n17. Subjects with Hematological and Oncological Diseases\u002FConditions\n18. Haemoglobin \\\u003C11.0 g\u002FdL (110 g\u002FL) for men; haemoglobin \\\u003C10.0 g\u002FdL (100 g\u002FL) for women\n19. Subjects with chronic disease e.g. Cancer, Epilepsy, Alzheimer, Parkinson\n20. Subjects with abnormal free T4\n21. Subjects with serious active infection",{"count":552,"type":20},90,[294],"Type 2 diabetes (T2DM) is still very difficult to treat because current medicines mostly help with symptoms but don't stop the damage happening inside the pancreas. Many people who start on common treatments like Metformin, and even newer drugs like Ozempic, eventually stop responding to them. This is because these drugs don't address the real problem: the gradual loss of the pancreas' ability to make insulin and the body's increasing resistance to it.\n\nMyopharm is developing a new treatment called TriGlytza®, which combines existing medicines (Celecoxib and Valsartan) with Metformin. This new approach is designed to target the inflammation and biological pathways that cause ongoing damage in Type 2 diabetes, aiming to protect the pancreas and reduce insulin resistance. Early animal studies and past clinical trials with the individual drugs show promising results.\n\nThe number of people with Type 2 diabetes is expected to double by 2045, and the disease brings huge health and financial costs. It also raises the risk of heart disease, stroke, kidney damage, nerve problems, vision loss, certain cancers, and even conditions like Alzheimer's. Because of this, a treatment that addresses the root causes rather than just symptoms could make a major difference.\n\nTriGlytza® aims to provide a safe, affordable, and more effective long-term treatment than current options, helping people manage their diabetes better and avoid related health problems.",[26],[55,91,557,558,559,560],"Metformin","Myopharm","Valsartan","Celecoxcib","2025-08-17",{"date":563,"type":31},"2025-08-24",{"date":565,"type":20},"2026-02",{"date":155,"type":20},{"name":568,"class":68},"Myopharm Limited",{"id":570,"slug":571,"hasResults":11,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":21,"phases":578,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":4},"100602809","cgm-use-in-non-insulin-patients-with-dm2-100602809","NCT07128342","CGM Use in Non-insulin Patients With DM2","Use of Continuous Glucose Monitoring in Veterans With Uncontrolled Diabetes Managed Without Insulin Therapy","CGM-DWI","Inclusion Criteria:\n\n* Successfully enrolled and ready to begin the VDOP program not on insulin therapy\n* Type 2 diabetes by clinical history\n* HbA1C between 8.0-12.0% inclusive within 3 months of enrollment\n* Assessment by clinician that patient is willing to and able to wear a CGM device\n* Stable diabetes medication regimen during the 3 months prior to entry\n\nExclusion Criteria:\n\n* Patients already or planned on starting insulin therapy, already on CGM, or those who qualify for CGM under VA policy\n* Patients with gestational diabetes or pregnant at time of screening or are planning to become pregnant during the study\n* Patients with end stage renal disease (ESRD) on dialysis\n* Anticipated acute uses of glucocorticoids (oral, injectable, or IV)\n* Acute conditions that impact the HbA1c measurement stability such as GI blood loss, recent (within 3 months of study entry), anticipated red blood cell transfusion or erythropoietin administration\n* Known or suspected significant allergy to use the Dexcom sensors\n* Planning or currently enrolled on different weight program different from MOVE!\n* Participating other clinical trials",{"count":263,"type":20},[140],"The U.S. Food and Drug Administration (FDA) has approved multiple Continuous Glucose Monitoring (CGM) devices from different manufacturers to be used as an aide in patients with type 1 and type 2 diabetes who require medications, and more recently, as over the counter versions for patients with and or without diabetes who want to better understand how diet and exercise may impact blood sugar levels. However robust evidence supporting that CGM is significantly superior to traditional home fingerstick blood glucose monitoring (FSBGM) in this population is lacking. Thus, Medicare and VHA only authorize use of CGM for patients with diabetes who require daily insulin therapy , unless they meet special criteria such as having hypoglycemia or inability to monitor glucose via traditional FSBGM.\n\nObjectives Primary Study Aim: Among veterans with uncontrolled diabetes not requiring insulin therapy who are participating in an intensive multidisciplinary program to improve diabetes control (VDOP), to assess whether use of a CGM compared to use of traditional FSBGM results in greater change in hemoglobin A1c upon VDOP completion and up to 12 months.\n\nSecondary study aims: To assess whether use of CGM in this population leads to greater improvement in diet, physical activity, and weight loss upon VDOP completion and up to 12 months.\n\nHypothesis\n\nThe use of a CGM by Veterans with T2DM who do not use insulin will help them improve their diabetes self - management (diet, physical activity, weight) and glycemic control more so than those using traditional fingerstick glucose monitoring.\n\nMethods\n\nThis will be a prospective \"open label\" randomized controlled trial where participants will be randomly assigned to CGM (intervention group) or FSBGM (control group) during their participation in VDOP.\n\nRelevance to Veterans and VA mission\n\nMost Veterans with T2DM do not use insulin. It is important for both, these Veterans and the VA, to learn whether this more costly and somewhat burdensome technology supports improvement in diabetes self-management",[91,26,581,582],"Obesity Type 2 Diabetes Mellitus","Non Insulin Dependent Diabetes Mellitus","2025-08-12",{"date":585,"type":31},"2025-08-18",{"date":587,"type":20},"2025-11-01",{"date":589,"type":20},"2028-11",{"name":591,"class":592},"Milwaukee VA Medical Center","FED",{"id":594,"slug":595,"hasResults":11,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":21,"phases":603,"briefSummary":604,"conditions":605,"keywords":607,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":614,"locationsCount":39},"100600210","personalized-hypoglycemia-outpatient-treatment---a-feasibility-study-100600210","NCT07094529","Personalized Hypoglycemia Outpatient Treatment - a Feasibility Study","The Feasibility of Personalized Hypoglycemia Outpatient Treatment for People Living With Type 2 Diabetes Mellitus","PHOT","Inclusion Criteria:\n\n* In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n  1. Consent provided\n  2. Age \\>= 18 years.\n  3. Diagnosed as type 2 diabetes mellitus.\n  4. Type 2 diabetes medications include at least one of the following for at least one month prior to entering the study: sulfonylurea or insulin of any type.\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  1. Diagnosed as another form of diabetes mellitus.\n  2. Has a history of hypoglycemia unawareness.\n  3. Had a hypoglycemia event, defined as capillary blood glucose \\\u003C 3.9 mmol\u002FL within 24 hours prior to the study visit booking time.",{"count":602,"type":20},120,[140],"This study will offer two study interventions designed to bring on a mild low blood sugar (capillary blood glucose result 3.0 to 3.8 mmol\u002FL), in order to study the effectiveness of each study participant's personal choice of treatment and first recheck time.\n\nThe two study interventions that the participant can choose to complete (one or both interventions).\n\nBased on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple carbohydrate treatment quantities, and choose one of 4 capillary blood glucose recheck times.",[26,606],"Hypoglycemia (Diabetic)",[608],"hypoglycemia","2025-07-23",{"date":476,"type":31},{"date":612,"type":31},"2025-07-21",{"date":280,"type":20},{"name":615,"class":68},"Ottawa Hospital Research Institute",{"id":617,"slug":618,"hasResults":11,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":290,"enrollmentInfo":623,"targetDuration":4,"studyType":21,"phases":625,"briefSummary":626,"conditions":627,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":4},"100596500","phase-3-phase-iii-clinical-study-on-the-efficacy-and-safety-of-semaglutide-and-ozempic-in-patients-with-type-2-diabetes-100596500","NCT07046273","Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes","A Multicenter, Randomized, Open, Parallel-controlled, Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n* 1\\) Voluntary signing of informed consent; 2) Aged 18-75 years (inclusive) at the time of signing the informed consent, male or female; 3) Diagnosed with type 2 diabetes according to the WHO diabetes diagnostic criteria; 4) Laboratory tests at the research center at screening: 7.5%≤HbA1c≤10.5%; 5) Before randomization, study participants received stable doses of metformin (≥1500mg\u002Fday or maximum tolerated dose: \\\u003C1500mg\u002Fday, but ≥1000mg\u002Fday) for at least 8 weeks (maximum tolerated dose must be supported by previous medical records); 6) Body mass index (BMI) ≥18.5kg\u002Fm2 and ≤35.0kg\u002Fm2 at screening; 7) Willing and able to undergo treatment and follow-up as required by the protocol.\n\nExclusion Criteria:\n\n1. Type 1 diabetes, special type of diabetes;\n2. Received hypoglycemic drugs other than metformin (including Chinese medicine) within 8 weeks before randomization;\n3. Used non-diabetes treatment drugs that may have a significant impact on glucose metabolism for 1 week or more within 3 months before randomization, such as glucocorticoids (systemic glucocorticoids used for \\\u003C7 days, excluding inhalation, ocular medication or topical application), sympathetic nerve stimulants (such as isoproterenol, dopamine, atropine, etc.), growth hormone, high-dose salicylates (300 mg\u002Fday and above), danazol, octreotide and anabolic androgenic steroids (such as oxymetholone, oxandrolone, etc.);\n4. Has a history of ≥2 episodes of grade 3 hypoglycemia within 1 year before randomization;\n5. Diabetic ketoacidosis or hyperglycemic hyperosmolar state within 3 months before randomization;\n6. Severe complications of diabetes at screening: such as proliferative diabetic retinopathy, macular edema; history of renal transplantation; severe peripheral vascular disease (such as amputation, chronic foot ulcers, intermittent claudication);\n7. Untreated or poorly controlled hypertension (defined as systolic blood pressure ≥160mmHg and\u002For diastolic blood pressure ≥100mmHg) at screening\u002Frandomization;\n8. Cardiovascular diseases such as acute coronary syndrome (including but not limited to acute myocardial infarction, or unstable angina), arrhythmia requiring treatment, severe heart failure (refer to New York Heart Association heart function grade III or IV), coronary artery bypass grafting or coronary stent implantation within 6 months before screening;\n9. New cerebrovascular accident (including ischemic stroke, hemorrhagic stroke and transient ischemic attack, etc.) within 6 months before screening;\n10. Severe trauma or severe infection or surgery that may affect blood sugar control within 1 month before screening;\n11. History of acute or chronic pancreatitis;\n12. History of cholecystitis due to cholelithiasis or other reasons within 6 months before screening;\n13. Cushing's syndrome, hyperthyroidism, and uncontrolled hypothyroidism at screening;\n14. Significant gastric emptying abnormalities (such as gastric outlet obstruction) and severe gastrointestinal diseases at screening;\n15. Any disease that may cause hemolysis or red blood cell instability and affect HbA1c detection, such as blood system tumors, hemolytic anemia, sickle cell disease;\n16. History or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);\n17. History of malignant tumors in the past 5 years (regardless of organ system, whether treated or not, and whether there is evidence of recurrence or metastasis) or currently being evaluated for potential malignant tumors, but excluding clinically cured cervical carcinoma in situ and skin basal cell carcinoma;\n18. Meet any of the following criteria at screening:\n\n    Liver function impairment: ALT or AST ≥ 5 times the upper limit of normal, or total bilirubin ≥ 2 times the upper limit of normal; Renal function impairment: glomerular filtration rate (eGFR, CKD-EPI formula) \\\u003C 45mL\u002Fmin\u002F1.73m2; Fasting triglyceride (TG) ≥ 5.7mmol\u002FL after stable medication; Calcitonin ≥ 50ng\u002FL; Hemoglobin ≤ 100g\u002FL; Thyrotropin (TSH) \\> 6mIU\u002FL after stable medication; Blood amylase or lipase ≥ 3 times the upper limit of normal; Hepatitis C virus antibody, human immunodeficiency virus antibody, syphilis serological test results are positive, hepatitis B virus surface antigen is positive and HBV-DNA is positive.\n19. Known allergy to any component of semaglutide injection or allergy to other GLP-1 RA drugs;\n20. Donated blood or lost ≥400mL of blood within 3 months before screening, or received blood transfusion therapy, or planned to donate blood during the trial;\n21. Received other clinical research drugs or device treatments within 3 months before screening, or participated in other drug clinical trials and are still within 5 half-lives of the trial drug, whichever is older; or planned to participate in other clinical studies during the trial;\n22. Have a history of drug abuse (including drug abuse) and\u002For alcohol dependence within 6 months before screening;\n23. Mental disorder or language barrier, unable to fully understand and cooperate;\n24. Pregnant or lactating women;\n25. Male and female research participants who have fertility plans during the trial and within 2 months after the last dose of the trial drug, or are unwilling to take reliable contraceptive measures for contraception;\n26. Other situations that the researcher considers unsuitable for participation in this study. -",{"count":624,"type":20},496,[23],"This study is a multicenter, randomized, open, parallel-controlled, Phase III clinical study aimed to evaluate the efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes.",[26],"2025-06-23",{"date":630,"type":31},"2025-07-01",{"date":632,"type":20},"2025-08-01",{"date":634,"type":20},"2029-02-01",{"name":636,"class":38},"Shandong New Time Pharmaceutical Co., LTD"]